Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30

$34.33−1.76 (-4.88%)

Close on Nov 13, 2026Market cap $1.91BP/E –Yield –

Maze Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Maze Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?